In Vivo Biocompatibility of Synechococcus sp. PCC 7002-Integrated Scaffolds for Skin Regeneration

Area of Science:

• Biomedical Engineering
• Microbiology
• Immunology

Background:

• Cyanobacteria, including Synechococcus sp. PCC 7002, are explored for medical uses like skin regeneration.
• Synechococcus sp. PCC 7002 is genetically modifiable and proliferates rapidly, making it a candidate for producing therapeutic agents.

Purpose of the Study:

• To evaluate the systemic safety of Synechococcus sp. PCC 7002 in skin regeneration scaffolds using a murine model.
• To assess systemic inflammatory responses and toxicity associated with bacterial colonization in scaffolds.

Main Methods:

• Comparison of three groups: scaffolds with engineered bacteria (hyaluronic acid-producing), wild-type bacteria, and no bacteria (control).
• Assessment of systemic inflammation after seven days via cytokine profiles and lymphatic organ weights (spleen, thymus, lymph nodes).
• Proteome profiling to analyze protein expression patterns related to inflammation and immune response.

Main Results:

• No significant differences in spleen, thymus, or lymph node weights were observed, indicating a lack of overt systemic toxicity.
• Elevated Interleukin-6 (IL-6) and Interleukin-1 beta (IL-1β) levels in blood suggested a systemic inflammatory response to bacterial presence.
• Proteome analysis revealed acute inflammation markers with bacterial colonization and a rejection response in control scaffolds.

Conclusions:

• Synechococcus sp. PCC 7002 in scaffolds does not appear to cause significant systemic toxicity, supporting its potential in biomedical applications.
• Bacterial colonization elicits an acute inflammatory response, while the absence of bacteria may trigger a rejection response.
• Further investigation into long-term effects and clinical implications of these immune responses is warranted.